NCT03913559 2026-02-12Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic LeukemiaSt. Jude Children's Research HospitalPhase 2 Terminated5 enrolled
NCT00482053 2018-05-14Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCTStanford UniversityPhase 2 Terminated3 enrolled 13 charts